
We are developing a 3-in-1 #cancer killing #immunotherapy based on the unique properties of #myxoma.
Phoenix, Arizona
Joined January 2020
- Tweets77
- Following69
- Followers104
- Likes34
Pinned Tweet
We've closed a $50M financing to take our 3-in-1 #myxoma #immunotherapy into #clinicaltrials.
oncomyx.com/oncomyx-closes-5…
@LumiraVentures @BCapitalGroup, LYZZ Capital, @xerayacapital @CityHillVC @ASU @ASUBiodesign, Skysong Innovations, @AZBio @Biomed_PHX @PHXEconDev @MayorGallego
Join our CEO Steven Potts today at 4:15pm PT at #BIO2022 as he presents the latest on our multi-armed #myxomavirus and its #oncolytic #immunotherapy potential.
More info: bio.org/events/bio-internati…
#myxomavirus #cancer #cancers #oncology #Phoenix #PHX #biotech
Don't forget we are presenting at #BIO2022 this Wednesday!
Learn about our multi-armed #myxomavirus as a potential #cancer #immunotherapy.
More info: bio.org/events/bio-internati…
#cancers #oncology #oncolyticvirus #Phoenix #PHX #biotech
4
We will be presenting at #BIO2022. Join our CEO Steven Potts next Wednesday, June 15 to learn about our multi-armed #myxomavirus and its #cancer-combatting potential.
To register: bio.org/events/bio-internati…
#cancers #oncology #oncolyticviruses #immunotherapy #Phoenix #PHX #biotech
3
ICYMI @Oncotarget covered the potential of our multi-armed #myxomavirus as a new #immunotherapy approach to treat #multiplemyeloma.
Read or listen: oncotarget.org/2022/03/17/tr…
#cancer #cancers #oncology #myxoma #oncolyticviruses #oncolytic #immunotherapies #myeloma #bloodcancers
In our last post for #NationalCancerResearchMonth we are sharing an interview our cofounder @grantmcf_grant did with Pharma’s Almanac about how viruses can be used for good and how the #myxoma has natural #cancer killing abilities.
pharmasalmanac.com/r250-trip…
#NCRM #cancerresearch
2
Thank you, @InBusinessPHX for speaking with our CEO on the scientific innovation happening right here in #Phoenix. We are proud to be part of the #AZ #biomedical community as we develop #cancer-fighting therapies.
inbusinessphx.com/economy-tr…
#biotech #oncology #cancers #myxoma
In a recent article, our cofounder @grantmcf_grant spoke with @NaturePortfolio on the next generation of #oncolyticviruses and #cancer-fighting #immunotherapies.
Read more: nature.com/articles/s43856-0…
#myxoma #myxomavirus #cancers #oncolytic #immunotherapy #oncology
1
Recently, our cofounder @grantmcf_grant spoke with @ASUResearch on the #cancer-fighting potential of #oncolyticviruses to improve human health. Thank you #ASUResearch for fostering a #community of scientific #innovation in #Phoenix.
research.asu.edu/about-us/ye…
#AZ #biotech #myxoma
Powerful partnerships.
Innovation.
Commitment to the community.
At the research and innovation engine of @ASU that is Knowledge Enterprise, these are some ways that we achieve our objective to change how the world solves problems. #ASUResearch
More: research.asu.edu/about-us/ye…
May is #NationalCancerResearchMonth. An analysis in 2021 found that ~7% of patients respond to genome-targeted therapy. We are committed to developing new #oncolytic #immunotherapies and targeted treatments to help more #cancer patients.
#NCRM22 #oncology #myxoma #myxomavirus
1
OncoMyx Presents New Data at #AACR22 Demonstrating Multi-Armed #Myxoma Virus Coordinates Tumor-Killing by Activating Innate and Adaptive Immune Response
oncomyx.com/oncomyx-presents…
#cancer #cancers #oncology #myxomavirus #oncolyticviruses #immunotherapy #multiplemyeloma #myeloma
Today we announce the appointment of Robert Williamson as Chief Business and Chief Financial Officer. Mr. Williamson has > 20 years of experience in building, financing, and leading biotech companies through critical phases of growth.
oncomyx.com/oncomyx-appoints…
#biotech #phoenix
.@Tech_Networks spoke with our cofounder @grantmcf_grant about harnessing the #oncolytic potential of the #myxomavirus to induce an anti-#tumor response to combat #cancer.
Read the article here: technologynetworks.com/cance…
#myxoma #immunotherapy #cancers #tumors
For @WomenScienceDay, we asked our Chief Scientific Officer, Dr. Leslie Sharp for a piece of career advice. She highlighted the different types of mentors that #womeninscience need. Here’s a good article on the topic. #womeninSTEM #EqualityInScience
hrdailyadvisor.blr.com/2018/…
4
#Phoenix is hot and so is the science. At the heart of #DTPHX, scientific innovation is heating up at @Biomed_PHX. We're proud to be part of this community that supports our development of #cancer-fighting therapies.
dtphx.org/2022/02/01/innovat…
#AZ #biotech @downtownphoenix @ASU
#WorldCancerDay is today, and we are helping to raise awareness of some common #cancer signs and symptoms. While symptoms may vary, early detection can be helpful in #cancerprevention.
Learn more at: worldcancerday.org/what-canc…
New year, new #job? We are looking for a CBO that is passionate about fighting #cancer and experienced in #businessdevelopment. Help our team advance a new #immunotherapy platform: oncomyx.com/careers/
#careers #biotech #westcoast #lifesciences #cancer #nowhiring #jobopening
Want to learn more about the #myxomavirus and its #cancer-combatting potential? Here’s a summary of a review written by our cofounder @grantmcf_grant
news-medical.net/news/202111…
#precisionmedicine #oncology #cancers #immunotherapies #oncolytic #oncolyticvirus #myxoma @ASUBiodesign
Thank you!
1
OncoMyx retweeted
We are proud to partner with @OncoMyx on this next stage of their growth. Congratulations to the OncoMyx team!
cc: @doctorrem, @Widya__Mulya, Megan Kotrappa
We've closed a $50M financing to take our 3-in-1 #myxoma #immunotherapy into #clinicaltrials.
oncomyx.com/oncomyx-closes-5…
@LumiraVentures @BCapitalGroup, LYZZ Capital, @xerayacapital @CityHillVC @ASU @ASUBiodesign, Skysong Innovations, @AZBio @Biomed_PHX @PHXEconDev @MayorGallego
OncoMyx retweeted
In this week’s #Arizona #Bioscience News, @OncoMyx, an @ASU spinout, receives $50M in funding to advance its #myxoma #immunotherapy into #clinicaltrials. Plus @azcommerce Arizona Innovation Challenge winners and more. https://teapawt.net/t.co/PWSc24RnxK



















